Position in CELC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$355,708,000
-$29,514,500 QoQ
Shares Held
3,400,000
+0.7% QoQ
Ownership
6.95%
of shares outstanding
% of Portfolio
3.19%
of 13F equity value
Holder Rank
#2
of 273 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Derivatives in CELC
reported options exposure · as of Mar 31, 2026CallValue
$3,050,000
CallShares
200,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Avoro Capital Advisors LLC holds $9,631,167,263 across 25 Biotechnology names. CELC ranks #9 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
5,111,111 | $1,363,235,525 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
2,888,888 | $1,073,713,002 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,833,333 | $984,408,154 | |
| 4 | ARGX |
Argenx SE
|
1,000,000 | $927,770,000 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
11,355,555 | $925,591,288 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
7,474,747 | $857,129,238 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
2,297,000 | $430,182,160 | |
| 8 | CYTK |
Cytokinetics Inc
|
4,999,999 | $425,949,914 |
All Filings in CELC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $355,708,000 | 3,400,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,050,000 | 200,000 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $385,222,500 | 3,375,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $310,302,211 | 3,111,111 | Shares | Sole | 2026-03-16 | |
| No filing history on record for this holder in this stock. | ||||||